New blood test to measure heart attack risk: C‐reactive protein

Journal of Cardiovascular Nursing

Volumn 19, Issue 6, 2004, Pages 425-429

  Duffy, Joanne R ^a   Salerno, Maria ^a  

^a CATHOLIC UNIVERSITY OF AMERICA   (United States)

Author keywords

Cardiac marker; Hs CRP; Inflammation; Risk factor

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN;

BLOOD; HEART INFARCTION; HUMAN; IMMUNOLOGY; INFLAMMATION; MASS SCREENING; METABOLISM; METHODOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STANDARD;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; MASS SCREENING; MYOCARDIAL INFARCTION; PATIENT SELECTION; PRACTICE GUIDELINES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 16644393602     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200411000-00016     Document Type: Article

References (32)

1. Altman R. Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. Thromb J. 2003;1:4. Available at:.
2. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction. a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23:168-175.
3. Farmer, JA, Torre-Amione, G. Atherosclerosis and inflammation. Curr Atheroscler Rep. 2002;4:92-98.
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
5. Libby P. Atherosclerosis: the new view. Sci Am. 2002;286(5):46-53.
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
7. Pasceri V, Yeh ETH. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999;100:2124-2126.
8. Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Circulation. 1999;100:1148-1150.
9. Gotto AM. Statins and c-reactive protein: considering a novel marker of cardiovascular risk. Prev Cardiol. 2002;5(4):200-203.
10. Morrow DA, Rifai N, Antman E, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI IIA substudy. Thrombosis in myocardial infarction. Am Coll Cardiol. 1998;31:1460-1465.
11. Morrow DA, Ridker, PM. C-reactive protein, inflammation, and coronary risk. Med Clin North Am. 2000;84:149-161.
12. Yeh ETH, Wilkerson J. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107:370-372.
13. Quest Diagnostics. Go beyond lipid management to improve risk prediction with Cardio CRP. 2004. Available at:. Accessed Fubruary 12, 2004.
14. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ. 2000;321:199-204.
15. Libby P, Ridker PM. Novel inflammatory markers of coronary risk. Circulation. 1999;100:1148-1150.
16. Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2002;21:1584-1590.
17. American Heart Association Inc and the Centers for Disease Control and Prevention (AHA/CDC). AHA/CDC scientific statement, markers of inflammation and cardiovascular disease. Circulation. 2003;107:499-511.
18. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-1397.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP)-Adult Treatment Panel III (ATP III). JAMA. 2001;285:2486-2497.
20. Ridker PM, Rafie N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103(9):1191-1193.
21. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2002;342:836-843.
22. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363.
23. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. N Engl J Med. 2000;343:1139-1147.
24. Benamer H, Steg PG, Benessiano J, et al. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. Am J Cardiol. 1998;82:845-850.
25. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events: an 8 year follow up of 14,719 initially healthy American women. Circulation. 2003;107:391-397.
26. Roberts WL, Moulton SR, Spencer A. Evaluation of four automated high-sensitivity C-reactive protein methods; implications for clinical and epidemiological applications. Clin Chem. 2000;46(4):46-48.
27. Hobbs FD, Kenkre JE, Carter JH, et al. Reliability and feasibility of a new patient test for C-reactive protein in primary care. Br J Gen Pract. 1996;46(408):395-400.
28. American Heart Association. Heart Disease and Stroke Statistics. Dallas: American Heart Association; 2003.
29. Braun L, Davidson M. Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. J Card Nurs. 2003;18:44-49.
30. Rifai N. C-reactive protein and coronary heart disease: diagnostic and therapeutic implications for primary prevention. Cardiovasc Toxicol. 2001;1(2):153-157.
31. Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation. 2000;100:1958-1963.
32. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.